Adherent cell assays have lagged behind in automation, slowing drug discovery. Semarion’s SemaCyte® microcarrier platform streamlines these workflows by making adherent cells assay-ready, improving ...
The device, which was tested in an investigator-initiated trial, works by pushing tumor cells through fluid-filled chambers and sorting them based on how well they adhere to the chamber walls. When ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results